UY32670A - Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica - Google Patents

Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica

Info

Publication number
UY32670A
UY32670A UY0001032670A UY32670A UY32670A UY 32670 A UY32670 A UY 32670A UY 0001032670 A UY0001032670 A UY 0001032670A UY 32670 A UY32670 A UY 32670A UY 32670 A UY32670 A UY 32670A
Authority
UY
Uruguay
Prior art keywords
alpha
preparation
treatment
chronic fatigue
fatigue syndrome
Prior art date
Application number
UY0001032670A
Other languages
English (en)
Inventor
Quintana Garcia
Alegre Martin Jose
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY32670A publication Critical patent/UY32670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Abstract

Utilización de Alfa-1-antitripisina para la preparación de medicamentos para el tratamiento del Síndrome de Fatiga Crónica. La presente invención se refiere a la utilización de Alfa-1-antitrisina para la prepaparación de medicamentos eficaces para el tratamiento del Síndrome de Fatiga Crónica. Además, la presente invención se refiere a la utilización de plasma u otras formas terapéuticas con un contenido de Alfa-1-antitripsina suficiente para conseguir una dosis superior o igual a mg de Alfa-1-antitripsina por kg de peso corporal con una periodicidad entre 1 y 31 días.
UY0001032670A 2009-06-30 2010-05-27 Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica UY32670A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (1)

Publication Number Publication Date
UY32670A true UY32670A (es) 2011-01-31

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032670A UY32670A (es) 2009-06-30 2010-05-27 Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica

Country Status (17)

Country Link
US (1) US9205134B2 (es)
EP (1) EP2289540B1 (es)
JP (1) JP5231490B2 (es)
CN (1) CN101934071B (es)
AR (1) AR077123A1 (es)
AU (1) AU2010202203B2 (es)
BR (1) BRPI1002087B1 (es)
CA (1) CA2706212C (es)
CL (1) CL2010000575A1 (es)
ES (2) ES2332645B1 (es)
HK (1) HK1148198A1 (es)
MX (1) MX2010006125A (es)
NZ (1) NZ585890A (es)
PL (1) PL2289540T3 (es)
PT (1) PT2289540E (es)
RU (1) RU2436590C1 (es)
UY (1) UY32670A (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502370A (ja) * 2011-12-19 2015-01-22 エルエフビー ユーエスエー インコーポレイテッドＬｆｂ Ｕｓａ， Ｉｎｃ． 炎症性疾患の治療のための組換えヒトα１−抗トリプシン
CN105263319A (zh) 2013-02-13 2016-01-20 法国化学与生物科技实验室 具有经修饰的糖基化的蛋白及其生产方法
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
ATE312608T1 (de) * 2000-04-21 2005-12-15 Pharmacia & Upjohn Co Llc Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
EP1302770A4 (en) * 2000-07-14 2004-09-15 Matsushita Electric Ind Co Ltd PARTICLE MARKING PROTEIN AND IMMUNO-CHROMATOGRAPHER USING THE SAME
AU2003286258B2 (en) 2002-11-20 2006-12-21 Arriva-Prometic Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US7344882B2 (en) * 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
WO2005019434A2 (en) * 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
EP1786923A1 (en) * 2004-09-07 2007-05-23 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
KR20100087291A (ko) * 2007-09-25 2010-08-04 아보트 러보러터리즈 케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물
PT2214699T (pt) 2007-11-02 2017-01-10 Grifols Therapeutics Inc Método, composição e artigo de fabrico para proporcionar alfa-1 antitripsina

Also Published As

Publication number Publication date
CN101934071B (zh) 2012-11-28
JP5231490B2 (ja) 2013-07-10
JP2011012060A (ja) 2011-01-20
RU2436590C1 (ru) 2011-12-20
BRPI1002087B1 (pt) 2019-07-02
EP2289540A1 (en) 2011-03-02
EP2289540B1 (en) 2012-08-22
ES2392691T3 (es) 2012-12-12
NZ585890A (en) 2011-11-25
CA2706212C (en) 2014-02-04
PL2289540T3 (pl) 2013-03-29
MX2010006125A (es) 2011-01-05
ES2332645A1 (es) 2010-02-09
CL2010000575A1 (es) 2011-10-28
BRPI1002087A2 (pt) 2012-03-13
ES2332645B1 (es) 2010-10-18
PT2289540E (pt) 2012-12-04
CA2706212A1 (en) 2010-12-30
AU2010202203A1 (en) 2011-01-20
US9205134B2 (en) 2015-12-08
CN101934071A (zh) 2011-01-05
US20100331261A1 (en) 2010-12-30
AR077123A1 (es) 2011-08-03
AU2010202203B2 (en) 2012-08-23
HK1148198A1 (en) 2011-09-02

Similar Documents

Publication Publication Date Title
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
MX2010005107A (es) Componente de silibinina para tratamiento contra hepatitis.
JP2016530291A5 (es)
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
UY32670A (es) Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
JP2011500589A5 (es)
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
AR080541A1 (es) Tratamiento para la endometriosis
AR054210A1 (es) Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia
AR113906A1 (es) Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
JP2010519274A5 (es)

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210226